// App-Quantinova.ai

556 : Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Researchers

Presenter

  • Oleg Gluz

Principal Investigators

  • Matthias Christgen

  • Ronald E. Kates

  • Michael Clemens

  • Stefan Kraemer

  • Benno Nuding

  • Toralf Reimer

  • Bahriye Aktas

  • Sherko Kummel

  • Marianne Just

  • Andrea Stefek

  • Fatemeh Lorenz-Salehi

  • Petra Krabisch

  • Cornelia Liedtke

  • Christer Svedman

  • Steven Shak

  • Rachel Wuerstlein

  • Hans Heinrich Kreipe

  • Nadia Harbeck

Medical Centers

  • West German Study Group, Moenchengladbach, Germany

  • Evangelic Hospital Bethesda, Moenchengladbach, Germany

  • Hannover Medical School, Hannover, Germany

  • REK Consulting, Otterfing, Germany

  • Mutterhaus der Borromaerinnen, Trier, Germany

  • Department of Obstetrics & Gynecology, University Hospital of Cologne, Cologne, Germany

  • Department of Obstetrics & Gynecology, Protestant Hospital Bergisch Gladbach, Bergisch Gladbach, Germany

  • Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany

  • University Hospital of Essen, Essen, Germany

  • Department of Senology / Breast Care Center, Kliniken Essen Mitte, Essen, Germany

  • Oncologic Practice Bielefeld, Bielefeld, Germany

  • Johanniter Krankenhaus, Genthin-Stendal, Germany

  • HSK Wiesbaden, Wiesbaden, Germany

  • Department of Gynecology and Obstetrics, Klinikum Chemnitz, Chemnitz, Germany

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Genomic Health, Inc., Redwood City, CA

  • LMU Munich, Munich, Germany

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

Locations

  • United States

  • Germany

Companies

  • REK Consulting

  • Genomic Health, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • Randomized

  • Prospective

Phase

  • III

Study Id's

  • NCT01049425

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved